TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average Price Target from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been given an average rating of "Buy" by the six analysts that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.33.

Several brokerages recently commented on TCRX. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Thursday, March 6th. Barclays reduced their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Morgan Stanley reissued an "overweight" rating and issued a $10.00 target price on shares of TScan Therapeutics in a research note on Friday, March 14th. Wedbush restated an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new position in shares of TScan Therapeutics in the fourth quarter valued at approximately $32,000. Prudential Financial Inc. acquired a new stake in TScan Therapeutics during the 4th quarter valued at $32,000. ProShare Advisors LLC bought a new position in TScan Therapeutics in the 4th quarter valued at $40,000. Wells Fargo & Company MN boosted its stake in TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after purchasing an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of TScan Therapeutics during the fourth quarter worth $59,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX traded up $0.11 during mid-day trading on Tuesday, hitting $1.24. The company had a trading volume of 346,807 shares, compared to its average volume of 348,970. TScan Therapeutics has a 12 month low of $1.02 and a 12 month high of $9.69. The firm has a market cap of $70.17 million, a P/E ratio of -1.17 and a beta of 1.09. The business's 50-day simple moving average is $1.74 and its 200-day simple moving average is $3.24. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.43 million. As a group, analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.